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RESEARCH ARTICLE
Frequency of Nuclear Mutant Huntingtin
Inclusion Formation in Neurons and Glia
is Cell-Type-Specific
Anne H.P. Jansen,1 Maurik van Hal,1 Ilse C. op den Kelder,1 Romy T. Meier,1
Anna-Aster de Ruiter,1 Menno H. Schut,2 Donna L. Smith,3 Corien Grit,4 Nieske Brouwer,4
Willem Kamphuis,5 H.W.G.M. Boddeke,4 Wilfred F.A. den Dunnen,4
Willeke M.C. van Roon,2 Gillian P. Bates,3 Elly M. Hol,5,6,7* and Eric A. Reits1*
Huntington’s disease (HD) is an autosomal dominant inherited neurodegenerative disorder that is caused by a CAG expansion
in the Huntingtin (HTT) gene, leading to HTT inclusion formation in the brain. The mutant huntingtin protein (mHTT) is ubiqui-
tously expressed and therefore nuclear inclusions could be present in all brain cells. The effects of nuclear inclusion formation
have been mainly studied in neurons, while the effect on glia has been comparatively disregarded. Astrocytes, microglia, and
oligodendrocytes are glial cells that are essential for normal brain function and are implicated in several neurological diseases.
Here we examined the number of nuclear mHTT inclusions in both neurons and various types of glia in the two brain areas
that are the most affected in HD, frontal cortex, and striatum. We compared nuclear mHTT inclusion body formation in three
HD mouse models that express either full-length HTT or an N-terminal exon1 fragment of mHTT, and we observed nuclear
inclusions in neurons, astrocytes, oligodendrocytes, and microglia. When studying the frequency of cells with nuclear inclu-
sions in mice, we found that half of the population of neurons contained nuclear inclusions at the disease end stage, whereas
the proportion of GFAP-positive astrocytes and oligodendrocytes having a nuclear inclusion was much lower, while microglia
hardly showed any nuclear inclusions. Nuclear inclusions were also present in neurons and all studied glial cell types in human
patient material. This is the first report to compare nuclear mHTT inclusions in glia and neurons in different HD mouse models
and HD patient brains.
GLIA 2016;00:000–000
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Introduction
Huntington’s disease (HD) is an autosomal dominantinherited neurodegenerative disorder. Patients suffer from
chorea, random involuntary movements, and several psychiat-
ric and cognitive symptoms such as mood changes, depres-
sion, and dementia. The prevalence of HD is 10.6–13.7
individuals per 100,000 in the Western world (Evans et al.,
2013; Fisher and Hayden, 2014; Morrison et al., 2011). HD
is caused by a CAG expansion in the Huntingtin (HTT) gene
resulting in a polyglutamine-expansion in the mutant HTT
protein (mHTT), and the formation of mHTT inclusions in
the nucleus and the cytoplasm of cells. While the appearance
of inclusions is an important hallmark of the disease, it is
debated whether these structures are toxic because the
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presence of inclusions is inversely correlated with neuronal
cell death in a cell model (Arrasate et al., 2004; Nucifora
et al., 2012).
HD-related research is primarily focusing on alterations
in the brain, and neurons have been studied mostly as they
seem to be the most affected cell type in HD. Glial cells have
been comparatively disregarded despite their critical role in
brain function. Both astrocytes and microglia directly regulate
synaptic communication: astrocytes take up neurotransmitters
from the synaptic cleft and release gliotransmitters that facili-
tate neuronal communication, and both microglia and astro-
cytes are involved in synaptic pruning and are responsive to
neurotransmitters (Chung et al., 2013; Kettenmann et al.,
2013; Pekny et al., 2016; Schafer et al., 2013). In HD
patients, astrocytes and microglia become activated, as shown
by the upregulation of glial fibrillary acidic protein (GFAP)
and thymosin b4, respectively, and the degree of activation
correlates with disease progression (Faideau et al., 2010; Sapp
et al., 2001). In mHTT gene carriers, microglia activation
occurs before the first symptoms become apparent as has
been shown using positron emission tomography (PK PET)
(Tai et al., 2007). Also, increased numbers of oligodendro-
cytes and GFAP-positive astrocytes are observed as early as
the first pathological stages in HD patients become manifest
(Faideau et al., 2010; Myers et al., 1991). Transgenic PLP-
HTT mice, expressing mHTT exclusively in oligodendrocytes,
show a progressive neurological phenotype and a reduced
myelin protein expression, which makes it clear that oligoden-
drocytes can be affected by mHTT expression (Huang et al.,
2015). Also, normal astrocyte functions are disturbed, as
shown by decreases in glutamate transporter levels, functional
glutamate transport, and the secretion of the neurotropic
molecule CCL5/RANTES (Chou et al., 2008; Shin et al.,
2005). In addition, alterations in potassium homeostasis
occur in HD astrocytes due to a decrease in the inward recti-
fier potassium channel Kir4.1 levels (Tong et al., 2014).
Astrocyte dysfunction contributes to HD, as astrocyte-specific
mHTT expression exacerbated the HD phenotype in dro-
sophila and mice (Bradford et al., 2010; Kretzschmar et al.,
2005). Microglia also change from their normal scanning
mode into an immune activated phenotype and start to accu-
mulate ferritin (Simmons et al., 2007). When expressing
mHTT, microglia secrete proinflammatory cytokines and
their migration toward chemotactic stimuli is impaired, prob-
ably because of defective actin remodeling (Kwan et al., 2012;
Silvestroni et al., 2009).
Despite the accumulating evidence that glial cells are
affected in HD mouse models and human HD patients, there
are only a few studies reporting the presence of mHTT inclu-
sions in astrocytes and oligodendrocytes (Huang et al., 2015;
Shin et al., 2005; Tong et al., 2014), and the presence of
inclusions in microglia has so far not been described. Here
we have assessed the proportion of different types of glia and
neurons with nuclear mHTT inclusions in the brain areas
that are most affected in the disease: frontal cortex and stria-
tum. We studied this in three commonly used HD mouse
models that show differences in disease progression. The R6/
2 model (Mangiarini et al., 1996) expresses the N-terminal
mHTT-exon 1 protein, and has a much faster progression of
symptoms and pathology when compared with the HdhQ150
and zQ175 HD mouse models that express full-length
mHTT (Lin et al., 2001; Menalled et al., 2012). Time points
selected for investigations were based on the phenotype seen
in the mice at a given age. Nuclear inclusions were also pre-
sent in neurons and all studied glial cell types in human
patient material. We found that proportion and size of nucle-
ar inclusions differs between the different cell types, with neu-
ronal inclusions being generally larger and more abundant
than nuclear inclusions in glia.
Materials and Methods
Mouse Models
In this study, 4, 9, and 14-week-old R6/2 mice (Mangiarini et al.,
1996), 2-, 16-, and 22-month-old homozygous HdhQ150 mice (Lin
et al., 2001), 3-, 6-, 8-, and 12-month-old heterozygous zQ175
mice (Menalled et al., 2012), and wild-type littermates were used.
The R6/2 mice analyzed had an average CAG expansion of 2106 4
(SD). The HdhQ150 homozygous mice used in this study had
expanded CAG repeat sizes of 1906 16 (SD) on the large allele and
1696 12 (SD) on the smaller allele. For the zQ175 line, we ana-
lyzed tissue with a mean CAG repeat expansion of 1936 4 (SD).
The end-stage phenotypes for R6/2 mice (13 weeks) and homozy-
gous HdhQ150 mice (22 months) are highly comparable (Kuhn
et al., 2007; Labbadia et al., 2011; Mielcarek et al., 2014, 2015;
Moffitt et al., 2009; Woodman et al., 2007), including the gross dis-
tribution of inclusions in the CNS (Woodman et al., 2007) and
periphery (Moffitt et al., 2009). The main difference between the
two lines is the age of phenotype onset and rate of disease progres-
sion (Lin et al., 2001). The zQ175 model originated from a sponta-
neous mutation in the chimeric knock-in model with 140 CAGs
(Menalled et al., 2003). In this model, HTT exon 1 is of human ori-
gin, whereas the rest of the Htt gene is murine. Progression of the
disease occurs more rapidly in both heterozygous and homozygous
zQ175 mice (Menalled et al., 2012) as compared with the
HdhQ150 model, and the end stage of disease occurs at approxi-
mately 20 months in zQ175 heterozygotes.
Isolation of Astrocyte and Microglia
Cell Populations
Wild-type mice—6 and 11 weeks old—were used in this experiment
(n5 12). The mice were anesthetized by i.p. injection of 100 mL
sodium pentobarbital and perfused with 0.9% NaCl (pH 5.5). All
experiments were performed according to the experimental animal
guidelines of the University Medical Center Groningen. Animals
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were housed under normal conditions in a 12-h light/dark cycle and
fed ad libitum in the central experimental animal facility of the Uni-
versity of Groningen. After dissecting the brains from the skull, the
cortex was isolated and cut into small pieces in ice-cold dissection
medium (Hanks bovine salt serum [HBSS], PAA, Cat.nr. H15-010;
1.3% D-(1)-glucose solution, Sigma, Cat.nr. G8769; 1.5% 4-(2-
hydroxyethyl)21-piperazineethanesulfonic acid [HEPES], PAA, 311-
001). Subsequently, the tissue was incubated in dissection medium
supplemented with papain (8.7 U/mL) and 0.5 mg/mL DNAse1 at
378C for 60 min. Enzyme digestion was stopped by adding fetal
bovine serum (FBS) to an end concentration of 10%. Tissue frag-
ments were triturated and 4 mL percoll (90% percoll, 150 mM
NaCl) was added to a volume of 3 mL dissection medium and cen-
trifuged at 200g with low brake at 48C for 20 min. The top phase
was discarded, and the Percoll layer containing the cells and the
myelin layer were collected and diluted five times using dissection
medium, followed by centrifugation at 200g at 48C for 10 min. To
avoid oligodendrocyte contamination, cell pellets were resuspended
in MACS buffer (2 mM Ethylenediaminetetraacetic acid [EDTA]
and 0.5% bovine serum albumin [BSA] in PBS pH 7.2) and incu-
bated with myelin removal beads (Miltenyi Biotec; 130-096-733) at
48C for 15 min. Subsequently, the samples were centrifuged at 200g
at 48C for 5 min, supernatant was discarded and cells were resus-
pended in MACS buffer. Cells were then loaded on MACS columns,
which were washed thrice with MACS buffer to elute the cells for
FACS sorting.
FACS Procedure
The obtained cell suspension was incubated with CD16/CD32
(1:100, eBioscience) to block Fc gamma receptors and prevent
monocyte isolation. After washing, cells were resuspended and incu-
bated with anti-GLT-1 (1:100, 0.6 mg/mL (Orre et al., 2014b) in
staining medium (HBSS, PAA, 1.3% D-(1)-glucose solution, Sigma,
Cat.nr. G8769; 1.5% HEPES, PAA, 311-001, 0.1 mM EDTA) at
48C for 30 min. After washing, cells were incubated with the sec-
ondary antibody anti-rabbit-Alexa488 (1:200) and the conjugated
antibodies CD45-PeCy7 (1:200 eBioscience) and CD11B-PE
(1:150, eBioscience) for 30 min at 48C. Cells were washed with
staining medium and 40,6-diamidino-2-fenylindool (DAPI) staining
was used to sort living cells. Using an MoFlo XDP sorter (Beckman
Coulter), GLT1 astrocytes were sorted based on a GLT1/CD11B2
expression and microglia were sorted on CD11B1/CD451 expres-
sion. The sorted cells were subjected to RNA isolation.
RNA Isolation and QPCR
RNA was isolated from the cells by adding TRIzol (400 lL, Thermo
Fisher) to the cell pellets, followed by addition of chloroform
(80 lL). Samples were centrifuged, the top phase was collected and
mixed with an equal volume of isopropanol and 1 lL glycogen
(20 mg/lL, Invitrogen). Samples were stored overnight at 2208C.
The next day, the samples were centrifuged (max. speed for 1 h at
48C) and pellets were washed twice with 75% ethanol. The total
sample was used as template for cDNA synthesis with a mix of oli-
go(dT) and random hexamer primers according to manufacturer’s
instructions (Quantitect-Qiagen). After DNAse treatment, the RNA
was incubated with reverse transcriptase for 30 min at 428C. The
samples were diluted 1:20 to serve as a template for real-time quan-
titative polymerase chain reaction (QPCR) analysis. QPCR was used
for the quantification of expression of endogenous Htt levels using
the primers 50-ATCTCAGCCAGTCTGGTGCT-30 and 50-
CCCACTGTTCTGGAGGTGTT-30. Hprt, Gapdh, Actg1, and
Acta1 were used for normalization.
Volcano plot analysis of proteomics data
of Sharma et al. 2015
The Volcano plots (Supp. Info., Fig. 1B) were generated by using
data of Sharma et al. (2015). In this study, neurons, microglia, astro-
cytes, and oligodendrocytes were isolated from 9-week-old C57BL/6
mice, which were used for proteomics analysis to determine cell-
type-specific expression patterns. The data were used to plot HTT
expression in each cell type in relation to their specific markers. In
the Volcano plot, Log2 protein intensity per cell type was plotted
against the median abundance of all cell types together.
Mouse Tissue Preparation for Immunofluorescence
Microscopy
All experimental procedures performed on mice were conducted under
a project license from the Home Office and approved by the King’s
College London Ethical Review Process Committee in the UK. Hemi-
zygous R6/2 mice were bred by backcrossing R6/2 males to (CBA 3
C57BL/6) F1 females (B6CBAF1/OlaHsd, Harlan Olac, Bicester,
UK). HdhQ150 homozygous mice on a (CBA 3 C57BL/6) F1 back-
ground were obtained by intercrossing HdhQ150 heterozygous CBA/
Ca and C57BL/6J congenic lines as described previously (Woodman
et al., 2007). zQ175 heterozygous mice were maintained by backcross-
ing to C57BL/6J females (Stock 000664, Charles River). All animals
were fed ad libitum (Special Diet Services, Witham, UK) and mice
were subjected to a 12-h light/dark cycle.
The mice were anesthetized by i.p. injection of 100 mL sodi-
um pentobarbital (juvenile mice< 5 weeks 50 mL) and perfused with
4% paraformaldehyde (PFA) in 0.1 M sodium phosphate buffer
(NaH2PO4, pH 7.4). After dissecting the brains from the skull, the
brains were postfixed in 4% PFA at 48C overnight. Brains were
stored in 0.1 M NaH2PO4/0.5% PFA until further use. Brains were
washed with phosphate-buffered saline (PBS, 154 mM NaCl,
1.1 mM KH2PO, 5.6 mM Na2HPO4, pH 7.4 Lonza) and incubated
in 20% sucrose in PBS overnight. Subsequently, brains were frozen
on dry ice and stored at 2808C. Brains were cut coronally in 10-
mm-thick sections that were mounted on Starfrost microscope slides
and stored at 2208C until further use. Two mice brains were ana-
lyzed for each time point, and the immunostaining experiments were
replicated at least once for each mouse.
Immunofluorescent Staining of Mouse
Tissue Sections
Sections were postfixed with 4% PFA for 15 min and washed with
PBS. Afterwards, the sections were heated for antigen retrieval in
10 mM sodium citrate1 0.05% tween-20 at 85–958C for 10 min.
Subsequently, sections were rinsed in PBS, blocked and permeabi-
lized with 1% BSA, 2% FBS, and 0.4% Triton X-100 in PBS for
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1 h, and incubated overnight with primary antibodies within the
same buffer. Antibodies used are listed in Table 1. Sections were sub-
sequently washed with PBS and incubated with fluorescent second-
ary antibodies donkey-anti-mouse, -rabbit, or -goat with Alexa488,
Cy3, or Cy5 tags to visualize immunostaining (1:700 Jackson Immu-
noResearch Laboratories). Finally, sections were washed in PBS and
embedded in Vectashield, including DAPI to stain nuclei (Vector
Laboratories). All procedures were performed at room temperature.
Human HD Patient Material and
Immunofluorescent Staining
Frontal cortex and striatum of 6 human HD patient cases were used
for analysis. Details are presented in Table 2 (Donor 1-6). Brain tissue
was formalin fixed and paraffin embedded. Sections of 6 mm were
used for immunostaining. Sections were deparaffinized and washed
with PBS. The staining procedure was similar as described for the
mouse tissue immunostaining using the same antibodies (Table 1).
TABLE 1: Antibodies
Company Species Dilution (mouse) Dilution (human) FACS dilution
NeuN Millipore (MAB377) Mouse monoclonal 1:500 1:500
S100B DAKO (Z0311) Rabbit polyclonal 1:4,500 1:600
GFAP DAKO (Z0334) Rabbit polyclonal 1:2,000 1:1,000
IBA1 Wako (019-19471) Rabbit polyclonal 1:4,000 1:1,000
OLIG2 Chemicon (Ab9610) Rabbit polyclonal 1:500 1:200
S829 (Sathasivam et al., 2001) Sheep polyclonal 1:800 1:500
GLT-1 (Orre et al., 2014b) Rabbit polyclonal 1:100
CD11B-PE eBioscience Rat monoclonal 1:150
CD45-PECy7 eBioscience Mouse monoclonal 1:200








grade Brain area Source
1 m >61 68 19/40 3 Frontal cortex W. den Dunnen (UMCG)
2 m >33 51 25/49 4 Frontal cortex W. den Dunnen (UMCG)
3 m >55 64 17/41 2 Frontal cortex W. den Dunnen (UMCG)
4 f 10 11 (JHD) 22/84 n.d. Caudate1 accumbens/frontal cortex W. van Roon (LUMC)
5 f 6 20 (JHD) 17/86 3 Caudate putamen/frontal cortex W. van Roon (LUMC)
6 m n.d. 37 (JHD) 15/68 3 Caudate putamen/frontal cortex W. van Roon (LUMC)
7 m Control 51 n.d. – Caudate1 accumbens/frontal cortex W. van Roon (LUMC)
8 m Control 54 n.d. – Striatum/frontal cortex W. van Roon (LUMC)
9 f Control 61 n.d. – Striatum/frontal cortex W. van Roon (LUMC)
10 f n.d. 57 23/43 4 Striatum/cortex W. van Roon (LUMC)
11 f 47 67 15/42 1 Cortex W. van Roon (LUMC)
12 m >70 80 17/42 2 Cortex W. van Roon (LUMC)
13 m 44 68 9/44 3 Cortex W. van Roon (LUMC)
14 m 15 40 (JHD) 18/53 3 Cortex W. van Roon (LUMC)
M5male; f5 female; VS grade5Vonsattel grade; n.d.5 no data available.
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Image Analysis
To determine the nuclear inclusion proportion per cell type, images
were taken with a Leica SP8 confocal microscope using a 633 oil
objective and Leica LAS X imaging software. A minimum of five
images was taken from each sample, the number of cells differed per
cell type ranging from 3 to 50 cells per field. Per image, the total
number of cell-marker-positive cells and the number of cells with
inclusions were counted. Per cell type a minimum of 200 cells were
included.
To quantify the number of cells in HD mice and their wild-
type littermates, images were acquired using a Leica DM RA micro-
scope equipped with a Plan Apo 253 1.40 oil objective (Carl Zeiss),
a cooled charge-coupled device camera (KX1400; Apogee Instru-
ments, Logan, UT, USA), and Image-Pro Plus software. DAPI-
stained nuclei were counted by a custom-made Matlab script. With
this script, the total nuclear surface area was measured and the num-
ber of distinct objects was counted. The number of positive cells was
counted manually by persons that were unaware of the mouse
genotypes.
Preparation of Insoluble Protein Fractions
Postmortem human brain tissue slides were homogenized with a bul-
let blender (Next Advance, strength 8, 3 min) in a buffer containing
150 mM sucrose, 15 mM HEPES pH7.9, 60 mM KCl, 0.5 mM
EDTA pH8, and 0.1 mM ethylene glycol-bis(b-aminoethyl ether)-
N,N,N0,N0-tetraacetic acid pH8 using a 1:5 weight-to-volume ratio.
After addition of Triton X-100 to a final concentration of 1%, sam-
ples were kept on ice for 1 h. Insoluble protein pellets were prepared
by centrifugation (max. speed for 10 min), and washed thrice with
60 mM Tris. Pellets were resuspended in 15% SDS and incubated
overnight at 958C. Protein concentration of resuspended pellets was
determined with the bicinchoninic (BCA) assay kit (Thermo Fisher
Scientific, Waltham, USA).
Filter-Trap Assay
One hundred micrograms of protein suspension in 300 mL of 15%
SDS was blotted onto a cellulose acetate membrane using a vacuum
applicator. Blots were washed twice with 0.2% SDS and fixed in
0.5% glutaraldehyde. Blots were blocked with 4% nonfat milk
(Nutricia, Schiphol, The Netherlands) in Tris-buffered saline with
Tween-20 and probed with primary anti huntingtin antibody 3702-1
(Epitomics, Burlinggame CA, USA), and secondary antibody horse
radish peroxidase conjugated goat-anti-rabbit (Santa Cruz). Blots
were visualized with enhanced chemoluminescence (ECL, #32106,
ThermoFisher) and Hyperfilm ECL (#28906837, GE healthcare,
Little Chalfond, United Kingdom). Signal intensity was quantified
with imageJ-software.
Statistics
Two-tailed unpaired Student’s t-test was used to assess differences in
RNA expression levels, P< 0.05 was accepted as significant. One-
way ANOVA with a Student–Newman–Keuls post hoc test was used
to assess differences in inclusion diameters in the various cell types.
The Marascuillo procedure was used to compare proportions of
inclusions in different cell types and to assess the number of cells in
wild-type and HD mice, for all tests significance level was set at
0.05. Supporting Information, Tables 1–4 display the results of all
statistical tests in detail.
Results
Huntingtin is Expressed in Neurons and Glia
Before quantifying the frequency of nuclear mHTT inclusions
in neuronal and glial cells, we examined the expression levels
of huntingtin in the various cell types of the mouse brain. By
data analysis of published transcriptomics and proteomics
studies, huntingtin mRNA and protein levels in neurons,
astrocytes, oligodendrocytes, and microglia could be deter-
mined (Supp. Info., Fig. 1). Whereas mRNA levels were
slightly higher in neurons compared with glia in both human
and mice (Supp. Info., Fig. 1A, data obtained from (Zhang
et al., 2016)), HTT protein levels were similar in oligoden-
drocytes, astrocytes, neurons, and microglia in mice (Sharma
et al., 2015). Compared with the median protein expression
levels of all these cell types combined (Log2 fold change, x-
axis), cell-specific markers were differentially expressed,
whereas HTT protein levels (Log2 protein expression intensi-
ties, y-axis) were comparable in all cell types (Supp. Info.,
Fig. 1B, analyzed data published by Sharma et al., 2015). Htt
mRNA expression in astrocytes and microglia was confirmed
by QPCR from cells isolated from wild-type mice using a
protocol developed earlier in our lab (Orre et al., 2014b) by
dissecting out the cortex and isolating dissociated GLT1
astrocytes and CD11B1/CD451 microglia by FACS. Htt is
expressed in astrocytes and microglia in young mice of 6 and
11 weeks old (Supp. Info., Fig. 1C). These results confirm
earlier data on Htt RNA expression in isolated astrocytes and
microglia in adult (3 months) and aged (15 months) mice
(Orre et al., 2014b).
Differences in Nuclear mHTT Inclusion Formation
between Neurons and Glial Cells in R6/2 Mice
While both cytoplasmic and nuclear inclusions were present
in R6/2 mice, we deliberately quantified only the nuclear
inclusions in neurons, astrocytes, oligodendrocytes, and
microglia as it is often difficult to determine whether cyto-
plasmic inclusions were present in particular cells due to the
complexity of brain tissue, and cell-specific markers do not
always label the entire cytoplasm. To determine whether the
frequency of nuclear mHTT inclusions differs between neu-
rons and the various glial cell types, we performed immuno-
fluorescent stainings on brain sections from R6/2 mice
(Mangiarini et al., 1996). The pathogenesis in R6/2 mice
progresses rapidly; inclusions have been observed at postnatal
day 0 (P0) and their number increases with age, with the first
phenotypes being present as early as P30 and the disease
reaching its end stage within 4 months (Stack et al., 2005).
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To visualize nuclear mHTT inclusions, we used the S829
antibody that was raised against the N-terminus of polyQ-
expanded HTT exon 1 (Sathasivam et al., 2001), in combina-
tion with at least one cell-type-specific marker. As GFAP
mainly labels reactive astrocytes, we also used S100B as a glial
marker to visualize also nonreactive astrocytes.
We analyzed the number of nuclear inclusions in neu-
rons, astrocytes, oligodendrocytes, and microglia in the frontal
cortex and striatum of mice aged 4, 9, and 14 weeks. Nuclear
inclusions were found in neurons, S100B-positive glial cells,
GFAP-positive astrocytes, oligodendrocytes, and microglia
(Fig. 1A), yet the proportion of these inclusions differed
between cell types. While the number of nuclear inclusions
increased with age in all cell types in both the frontal cortex
and the striatum, neurons contained the highest proportion
of nuclear inclusions (around 45% of neurons) at 14 weeks
in the frontal cortex. In the striatum, the fraction of S100B-
positive glial cells with nuclear inclusions was lower compared
with neurons (around 35%), whereas GFAP-positive astro-
cytes and oligodendrocytes showed an even lower percentage
(5–10% at 14 weeks). Strikingly, IBA1-positive microglia
hardly showed any nuclear inclusions at all, with 14-week-old
mice showing only nuclear inclusions in about 1% of the cells
(Fig. 1B and Supp. Info., Table 1). In general, nuclear inclu-
sions had a diameter of 1 mm in the cortex and 1–1.5 mm in
the striatum in the different types of glial cells. The nuclear
inclusions were significantly larger in neurons compared with
glia: about 2 mm at 14 weeks (Fig. 1C). In the striatum, neu-
ronal nuclear inclusions were also larger than those in glia at
14 weeks (Fig. 1C). The differences in the proportion of
nuclear inclusions between the different cell types was not
due to cell death as no differences were observed in the num-
ber of cells in wild-type brains and R6/2 brains (Fig. 1D and
Supp. Info., Table 2). Together, these data show that in the
R6/2 HD model, nuclear mHTT inclusions are more abun-
dant and larger in neurons compared with glia, with S100B-
FIGURE 1: Nuclear mHTT inclusions in R6/2 striatum and cortex. (A) Exemplary images of mHTT inclusions (S829, red) were present in
the nuclei (DAPI, blue) of neurons (NeuN, green, striatum), S100B-positive glia (green, striatum), GFAP-positive astrocytes (green, frontal
cortex), oligodendrocytes (OLIG2, green, striatum), and microglia (IBA1, green, frontal cortex). Representative pictures of each cell, mor-
phology similar in cortex and striatum. Scale bar is 3 mm. (B) The percentage of cells with a nuclear inclusion in the cortex and striatum.
(C) The change in the diameter of nuclear inclusions with disease progression in the various cell types. Different letters represent signifi-
cantly different groups as determined by one-way ANOVA with Student–Newman–Keuls post hoc test. (D) The percentage of nuclei co-
staining for various cell type markers. Cell numbers were similar between wild-type and R6/2 mice (N511,943–27,037). WT5wild-type.
[Color figure can be viewed at wileyonlinelibrary.com.]
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positive glial cells showing a higher proportion of nuclear
inclusions than GFAP-positive astrocytes or oligodendrocytes,
and that microglia hardly show any nuclear inclusion
formation.
Differences in Nuclear mHTT Inclusions
Between Neurons and Glial Cells in Knock-In
HD Mouse Models
We also examined the proportion of nuclear inclusions in the
various cell types in two knock-in HD mouse models that
express the full-length mHTT protein. The first was the
HdhQ150 model, where approximately 150 CAGs were
knocked into the mouse Htt gene (Lin et al., 2001). The sec-
ond full-length mHTT model was the zQ175 model, which
is chimeric for human HTT exon 1, with approximately 175
CAGs, and the remainder of the mouse Htt gene (Menalled
et al., 2012). Similar to the R6/2 model, nuclear inclusions
were found in all cell types studied in HdhQ150 mice (Fig.
2A), and the percentage of cells that had nuclear inclusions
was comparable to the R6/2 model. Neurons contained the
highest frequency of nuclear inclusions, closely followed by
S100B-positive glial cells. Around 10% of GFAP-positive
astrocytes and oligodendrocytes contained nuclear inclusions,
while microglia only incidentally contained nuclear inclusions
(Fig. 2B and Supp. Info., Table 1). Average nuclear inclusion
diameter in the HdhQ150 model was 1.3 mm in S100B-
positive glial cells, 1 mm in GFAP-positive astrocytes and oli-
godendrocytes, and 2 mm in neurons at the disease end stage
(Fig. 2C). We observed a significant 50% increase in GFAP
expression in the striatum (2, 16, and 22 months) and a 75%
increase in the frontal cortex (16 and 22 months) (Fig. 2D
and Supp. Info., Table 3), consistent with what was described
before (Lin et al., 2001). In addition, the number of S100B-
positive glial cells in both frontal cortex (16 months: 133%;
FIGURE 2: Nuclear mHTT inclusions in the homozygous HdhQ150 mouse striatum and cortex. (A) Exemplary images of mHTT inclusions
(S829, red) were present in nuclei (DAPI, blue) of neurons (NeuN, green, striatum), S100B-positive glia (green, striatum), GFAP-positive
astrocytes (green, striatum), oligodendrocytes (OLIG2, green, striatum), and microglia (IBA1, green, frontal cortex). Representative pic-
tures of each cell, morphology similar in cortex and striatum. Scale bar is 3 mm. (B) The percentage of cells with a nuclear inclusion in
the cortex and striatum. (C) The change in diameter of nuclear inclusions with disease progression in the various cell types. Different let-
ters represent significantly different groups as determined by one-way ANOVA with Student–Newman–Keuls post hoc test. (D) The per-
centage of nuclei co-staining for various cell type markers. Quantification of total cell numbers showed an increase in S100B-postive glia
and GFAP-positive astrocytes in HdhQ150 brains as compared with wild-type (minimum N510,005–20,879). WT5wild-type. [Color
figure can be viewed at wileyonlinelibrary.com.]
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22 months: 150%) and striatum (22 months: 193%) and
the number of microglia in the frontal cortex (22 months:
130%) were significantly increased at end-stage disease in
HdhQ150 mice.
Consistent with our R6/2 and HdhQ150 data, we
observed nuclear inclusions in the zQ175 sections in neurons
and all types of glia analyzed (Fig. 3A). The proportion of
cells containing a nuclear inclusion increased with disease
progression in both frontal cortex and striatum, and was com-
parable to the proportions observed in the other HD mouse
models (Fig. 3B and Supp. Info., Table 1). Neurons and
S100B-positive glial cells contained the highest proportion of
nuclear inclusions (around 35% of all cells) in both frontal
cortex and striatum, followed by the GFAP-positive astrocytes
and oligodendrocytes (around 5% of all cells), whereas nucle-
ar inclusions were hardly present in microglia. Although the
abundance of zQ175 nuclear mHTT inclusions was similar
to R6/2 and HdhQ150, all nuclear inclusions were slightly
smaller in this model (Fig. 3C), most likely reflecting the fact
that tissue from end-stage disease was not available. We
observed significantly lower numbers of neuronal cells in
both frontal cortex and striatum in 12-month-old zQ175
mice (frontal cortex: 227%; striatum: 241%); however, in
glia no major decrease in numbers were detected. So, similar
to R6/2 and HdhQ150, also in zQ175 mice the lower pro-
portion of nuclear inclusions in glial cells compared to neu-
rons is not due to glial cell death (Fig. 3D and Supp. Info.,
Table 4).
Comparison of HD Mouse Models with Human
HD Patient Material
Next to the three HD mouse models, we performed also dou-
ble labeling of HTT and cell-specific markers in the frontal
cortex and striatum from HD postmortem brains. The per-
centage of cells containing a nuclear inclusion (max. 0.3% in
neurons) was much lower in human patients compared with
FIGURE 3: Nuclear mHTT inclusions in the zQ175 model. (A) Exemplary images of HTT inclusions (S829, red) were present in the nuclei
(DAPI, blue) of neurons (NeuN, green, frontal cortex), S100B-positive glia (green, striatum), GFAP-positive astrocytes (green, frontal cor-
tex), oligodendrocytes (OLIG2, green, striatum), and microglia (IBA1, green, frontal cortex). Representative pictures of each cell, mor-
phology similar in cortex and striatum. Scale bar is 3 mm. (B) The percentage of cells with a nuclear inclusion in the cortex and striatum.
(C) The change in diameter of nuclear inclusions with disease progression in the various cell types. Different letters represent significant-
ly different groups as determined by one-way ANOVA with Student–Newman–Keuls post hoc test. (D) The percentage of nuclei co-
staining for various cell type markers. Quantification of cell numbers in wild-type mice and zQ175 mice (minimum N59,629–17,518).
WT5wild-type. [Color figure can be viewed at wileyonlinelibrary.com.]
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the HD mouse models (max 40–50% in neurons) (Fig. 4B).
In juvenile HD (JHD) patient brains, we found nuclear
inclusions in all cell types (Fig. 4A), and in a higher percent-
age of cells than in the adult onset HD brains (Fig. 4C).
This is consistent with increased insoluble HTT protein due
to the increase in Q length (Supp. Info., Fig. 2), although
filter-trap analysis showed that JHD 86Q sample produced
less aggregates than the 55Q sample. This could be related to
subject-to-subject variations or to the young age of the Juve-
nile HD patient with 86Q who died at the age of 11, where-
as the other patients were adults with the average age of 60.
Also in JHD, more nuclear inclusions were found in the frontal
cortex than in the striatum (Fig. 4C and Supp. Info., Fig. 2).
Discussion
While mHTT aggregation has been mainly observed and
studied in neurons, we investigated nuclear mHTT inclusions
in glial and neuronal cells in three commonly used HD
mouse models, the R6/2 transgenic model and the HdhQ150
and zQ175 knock-in models, and in adult and juvenile HD
patient postmortem brains. We showed that nuclear inclu-
sions are present in neurons, astrocytes, oligodendrocytes, and
microglia but with very different frequencies. Interestingly,
the three mouse models showed a similar percentage of nucle-
ar mHTT inclusion bearing cells in the cortex and striatum,
despite the expression of full-length mHTT or only mHTT
exon1. At late stages of the disease, nuclear inclusions were
found in 30–50% of the neurons, 30% of the S100B-positive
glial cells, 4–10% of the GFAP-positive astrocytes, 3–10% of
the oligodendrocytes, and 0–2% of the microglia. Both the
proportion of cells containing nuclear inclusions and the
nuclear inclusion size was lower in glial cells compared with
neurons. In neurons, nuclear inclusions were on average 2
mm in diameter, whereas glial nuclear inclusions measured
only 1 mm on average. Interestingly, only neuronal nuclear
inclusions changed in size with disease progression, increasing
from 0.6 mm to a maximum of 2 mm at the end stage. This
is in agreement with earlier findings in R6/2 mice, zQ175
mice, and human patients (Carty et al., 2015; Gutekunst
et al., 1999; Li et al., 1999). This suggests that nuclear inclu-
sions persist for a long period of time and increase in size,
most likely due to sequestration of newly synthesized mHTT
but also the sequestering of other proteins. As the nuclear
inclusions in all cell types were also positively immunostained
for ubiquitin (data not shown), this indicates that the used
S829 antibody against mHtt recognizes nuclear inclusions in
all cell types with similar efficiency. Interestingly, an increase
in nuclear inclusion size with disease progression was not
observed in glia, suggesting a better capability of these cells to
constrain mHTT inclusion size. As we did not find indica-
tions of cell death in glia, the stable nuclear inclusion size
and lower nuclear inclusion proportion in glia suggests that
the various glial cell types are better capable to slow down
mHTT aggregation. In addition, it has been suggested that
the cellular compartment influences inclusion structure due to
interaction with chaperones and other factors, so the compo-
sition of nuclear inclusions may be different in glia. Indeed,
it has been recently shown that brain material derived from
FIGURE 4: Nuclear mHTT inclusions in Huntington’s disease postmortem human brain. (A) Exemplary images of nuclear mHTT inclusions
(S829, red) were present in the nuclei (DAPI, blue) of neurons (NeuN, green, frontal cortex), S100B-positive glia (green, frontal cortex),
GFAP-positive astrocytes (green, striatum, frontal cortex), and microglia (IBA1, green, frontal cortex) oligodendrocytes (OLIG2, green,
frontal cortex). Representative pictures of each cell, morphology similar in cortex and striatum. Scale bar is 3 mm. (B) The proportion of
the various cell types that contain a nuclear inclusion in the frontal cortex of adult-onset patients. (C) The proportion of the various cell
types that contain a nuclear inclusion in the frontal cortex and striatum of juvenile-onset patients. [Color figure can be viewed at
wileyonlinelibrary.com.]
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HD patients contains a number of structurally different types
of inclusions, and that amorphous inclusions are less toxic
than fibrillary inclusions (Andre et al., 2013; Hoffner and
Djian, 2015). We deliberately quantified only the nuclear
inclusions in the studied cell types as the used markers for
co-staining did not label the entire cytoplasm, making it too
difficult to determine whether cytoplasmic inclusions were
indeed present in particular cells that were immunostained
for GFAP, NeuN, S100B, OLIG2, or IBA1.
Nuclear mHTT Inclusions in Astrocytes
Interestingly, there is a large diversion in the occurrence of
nuclear inclusions in S100B-positive glial cells (20–35%) com-
pared with GFAP-positive astrocytes (2–10%). S100B is not
exclusively expressed in astrocytes, but also in oligodendrocytes,
NG2 cells, and neurons (Vives et al., 2003). Immunostaining
experiments combining S100B with astrocyte markers GS and
ALdh1L1 showed that 50% of both GS and ALdh1L1 cells
were positive for S100B cells and vice versa. Co-staining S100B
with NeuN showed no co-staining of S100B with NeuN,
excluding neuronal staining by S100B (data not shown).
S100B and GFAP may represent different cell populations, as
GFAP is an astrocyte-specific protein but it is not expressed by
every astrocyte in mouse brains. GFAP is a marker for astroglio-
sis, a process where astrocytes become activated in response to
brain damage as a result of trauma, stroke, or in neurodegenera-
tive diseases (Hol and Pekny, 2015; Middeldorp and Hol,
2011; Pekny et al., 2016). Reactive astrocytes change their gene
expression profile toward a more proinflammatory phenotype,
including potential changes in protein homeostasis. Upregula-
tion of immunoproteasome components (catalytic subunits and
proteasome activator PA28ab) and several heat-shock proteins
(HSP70, HSPB1, and HSPB3) has been observed in reactive
astrocytes in the cortex of a mouse model for Alzheimer’s Dis-
ease (Orre et al., 2014a). As reactive astrocytes have an
increased proteasome activity, which correlates with GFAP
upregulation, this could explain the reduced proportion of
nuclear mHTT inclusions in GFAP-positive astrocytes (Mid-
deldorp et al., 2009; Orre et al., 2013). As the number of
GFAP-positive cells were not increased, it is unclear whether in
our models true reactive gliosis is observed.
Mechanisms behind Lower Number of Nuclear
Inclusions in Microglia
The number of inclusions is most likely related to mHtt pro-
tein levels, which is regulated by both mHTT synthesis and
degradation. mHTT expression has been determined at the
mRNA level in astrocytes, neurons, oligodendrocytes, and
microglia for both human and mice (Supp. Info., Fig. S1A).
The two studied full-length mHTT mouse models
(HdhQ150, zQ175) have the mouse Htt promotor/enhancer
region, resulting in similar levels of Htt expression compared
with endogenous Htt expression in wild-type mice. As the
expression level of mHTT is similar in neurons and glia, this
study is indicative of a cell-type-specific sensitivity for inclu-
sion formation with microglia being the least sensitive, while
neurons are most vulnerable. The surprisingly low proportion
of nuclear mHTT inclusions in microglia suggests that these
cells may be able to prevent the aggregation process. One
explanation could be that microglia are able to proliferate
under neurodegenerative conditions, in contrast to neurons
and astrocytes, as was demonstrated in both Alzheimer’s dis-
ease and HD (Kamphuis et al., 2012; Kraft et al., 2012).
This would result in reduced mHTT levels in their progeny,
thereby reducing the likelihood of inclusion formation. The
observed asymmetrical diversion of inclusions to one of the
daughter cells (Rujano et al., 2006) could also result in higher
number of daughter cells without inclusions. However, cell
proliferation cannot fully explain the discrepancy in the inclu-
sion proportion because we only observed major increases in
the number of astrocytes and microglia in the HdhQ150
model but not the other models used, and astrocytes only
proliferate in the adult brain to a limited extend (Kamphuis
et al., 2012). Besides, no clear microglia activation could be
observed in the mouse models. Next to the possibility that
microglia containing nuclear inclusions die and are replaced
by new cells, differences in protein degradation pathways may
underlie the observed dissimilarities in inclusion frequency in
mice. In HD patients, we observed activation of astrocytes
and microglia (data not shown), which is consistent with pre-
vious findings (Faideau et al., 2010; Sapp et al., 2001).
Immune activation is in AD associated with higher levels and
increased activity of immunoproteasome subunits in astro-
cytes and microglia (Orre et al., 2013) and autophagosomes
in microglia (Su et al., 2016). These changes can lead to a
more efficient degradation of aggregation-prone proteins and
thus might underlie the lower proportion of nuclear inclu-
sions in glia. In human HD patients, the number of inclu-
sions was much lower compared with mice, as previously
described (Seidel et al., 2016). However, in HD patients,
HTT is also present as neuropil inclusions/granular cytoplas-
mic structures (DiFiglia et al., 1997; Seidel et al., 2016). In
juvenile HD cases (JHD), more nuclear inclusions were pre-
sent (Fig. 4C) as previously described (DiFiglia et al., 1997),
whereas the used mouse models have even longer polyglut-
amine repeats compared with human patients. So, while these
HD mouse models may not be representative for the human
situation in terms of the absolute number of nuclear inclu-
sions, these models provide a valuable insight in the relative
differences between multiple cell types in relation to inclusion
formation.
10 Volume 00, No. 00
Acknowledgments
The authors thank Jan Ruijter for the statistical advice, the
core facility Cellular Imaging at the AMC, and especially
Ron Hoebe for the technical assistance and Harm Kampinga
for the provision of the R6/2 mice for the glia isolations. A.J.
was funded by an AMC PhD scholarship.
Conflict of Interest
The authors have no conflict of interest.
References
Andre W, Sandt C, Dumas P, Djian P, Hoffner G. 2013. Structure of inclusions
of Huntington’s disease brain revealed by synchrotron infrared microspectro-
scopy: Polymorphism and relevance to cytotoxicity. Anal Chem 85:
3765–3773.
Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. 2004. Inclusion
body formation reduces levels of mutant huntingtin and the risk of neuronal
death. Nature 431:805–810.
Bradford J, Shin J, Roberts M, Wang C, Sheng G, Li S, Li X. 2010. Mutant
huntingtin in glial cells exacerbates neurological symptoms of Huntington dis-
ease mice. J Biol Chem 285:10653–10661.
Carty N, Berson N, Tillack K, Thiede C, Scholz D, Kottig K, Sedaghat Y,
Gabrysiak C, Yohrling G, von der Kammer H, Ebneth A, Mack V, Munoz-
Sanjuan I, Kwak S. 2015. Characterization of HTT inclusion size, location, and
timing in the zQ175 mouse model of Huntington’s disease: an in vivo high-
content imaging study. PLoS One 10:e0123527.
Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH, Dickson DW, Chern Y.
2008. Expanded-polyglutamine huntingtin protein suppresses the secretion
and production of a chemokine (CCL5/RANTES) by astrocytes. J Neurosci 28:
3277–3290.
Chung WS, Clarke LE, Wang GX, Stafford BK, Sher A, Chakraborty C, Joung
J, Foo LC, Thompson A, Chen C, Smith SJ, Barres BA. 2013. Astrocytes
mediate synapse elimination through MEGF10 and MERTK pathways. Nature
504:394–400.
DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N.
1997. Aggregation of huntingtin in neuronal intranuclear inclusions and dys-
trophic neurites in brain. Science 277:1990–1993.
Evans SJ, Douglas I, Rawlins MD, Wexler NS, Tabrizi SJ, Smeeth L. 2013.
Prevalence of adult Huntington’s disease in the UK based on diagnoses
recorded in general practice records. J Neurol Neurosurg Psychiatry 84:
1156–1160.
Faideau M, Kim J, Cormier K, Gilmore R, Welch M, Auregan G, Dufour N,
Guillermier M, Brouillet E, Hantraye P, Deglon N, Ferrante RJ, Bonvento G.
2010. In vivo expression of polyglutamine-expanded huntingtin by mouse
striatal astrocytes impairs glutamate transport: a correlation with Huntington’s
disease subjects. Hum Mol Genet 19:3053–3067. doi: 10.1093/hmg/ddq212.
Epub 2010 May 21.
Fisher ER, Hayden MR. 2014. Multisource ascertainment of Huntington dis-
ease in Canada: prevalence and population at risk. Mov Disord 29:105–114.
Gutekunst CA, Li SH, Yi H, Mulroy JS, Kuemmerle S, Jones R, Rye D,
Ferrante RJ, Hersch SM, Li XJ. 1999. Nuclear and neuropil aggregates in
Huntington’s disease: relationship to neuropathology. J Neurosci 19:
2522–2534.
Hoffner G, Djian P. 2015. Polyglutamine aggregation in Huntington disease:
Does structure determine toxicity? Mol Neurobiol 52:1297–1314.
Hol EM, Pekny M. 2015. Glial fibrillary acidic protein (GFAP) and the astro-
cyte intermediate filament system in diseases of the central nervous system.
Curr Opin Cell Biol 32:121–130.
Huang B, Wei W, Wang G, Gaertig M, Feng Y, Wang W, Li X, Li S. 2015.
Mutant huntingtin downregulates myelin regulatory factor-mediated myelin
gene expression and affects mature oligodendrocytes. Neuron 85:
1212–1226.
Kamphuis W, Orre M, Kooijman L, Dahmen M, Hol EM. 2012. Differential cell
proliferation in the cortex of the APPswePS1dE9 Alzheimer’s disease mouse
model. GLIA 60:615–629.
Kettenmann H, Kirchhoff F, Verkhratsky A. 2013. Microglia: New roles for the
synaptic stripper. Neuron 77:10–18.
Kraft AD, Kaltenbach LS, Lo DC, Harry GJ. 2012. Activated microglia prolifer-
ate at neurites of mutant huntingtin-expressing neurons. Neurobiol Aging 33:
621.e17–621.e33.
Kretzschmar D, Tsch€ape J, Bettencourt Da Cruz A, Asan E, Poeck B, Strauss
R, Pflugfelder GO. 2005. Glial and neuronal expression of polyglutamine pro-
teins induce behavioral changes and aggregate formation in Drosophila.
GLIA 49:59–72.
Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C,
Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR,
Leavitt BR, Dunnett SB, Ferrante RJ, Albin R, Shelbourne P, Delorenzi M,
Augood SJ, Faull RL, Olson JM, Bates GP, Jones L, Luthi-Carter R. 2007.
Mutant huntingtin’s effects on striatal gene expression in mice recapitulate
changes observed in human Huntington’s disease brain and do not differ
with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol
Genet 16:1845–1861.
Kwan W, Trager U, Davalos D, Chou A, Bouchard J, Andre R, Miller A, Weiss
A, Giorgini F, Cheah C, Moller T, Stella N, Akassoglou K, Tabrizi SJ,
Muchowski PJ. 2012. Mutant huntingtin impairs immune cell migration in
Huntington disease. J Clin Invest 122:4737–4747.
Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, Seredenina T,
Woodman B, Moussaoui S, Frentzel S, Luthi-Carter R, Paganetti P, Bates GP.
2011. Altered chromatin architecture underlies progressive impairment of the
heat shock response in mouse models of Huntington disease. J Clin Invest
121:3306–3319.
Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. 1999. Ultrastructural
localization and progressive formation of neuropil aggregates in Huntington’s
disease transgenic mice. Hum Mol Genet 8:1227–1236.
Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse
AB, Ren S, Li XJ, Albin RL, Detloff PJ. 2001. Neurological abnormalities in
a knock-in mouse model of Huntington’s disease. Hum Mol Genet 10:
137–144.
Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C,
Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. 1996. Exon 1 of the
HD gene with an expanded CAG repeat is sufficient to cause a progressive
neurological phenotype in transgenic mice. Cell 87:493–506.
Menalled LB, Kudwa AE, Miller S, Fitzpatrick J, Watson-Johnson J, Keating
N, Ruiz M, Mushlin R, Alosio W, McConnell K, Connor D, Murphy C,
Oakeshott S, Kwan M, Beltran J, Ghavami A, Brunner D, Park LC, Ramboz S,
Howland D. 2012. Comprehensive behavioral and molecular characterization
of a new knock-in mouse model of Huntington’s disease: zQ175. PLoS One
7:e49838.
Menalled LB, Sison JD, Dragatsis I, Zeitlin S, Chesselet MF. 2003. Time
course of early motor and neuropathological anomalies in a knock-in mouse
model of Huntington’s disease with 140 CAG repeats. J Comp Neurol 465:
11–26.
Middeldorp J, Hol EM. 2011. GFAP in health and disease. Prog Neurobiol
93:421–443.
Middeldorp J, Kamphuis W, Sluijs JA, Achoui D, Leenaars CHC, Feenstra
MGP, van Tijn P, Fischer DF, Berkers C, Ovaa H, Quinlan RA, Hol EM. 2009.
Intermediate filament transcription in astrocytes is repressed by proteasome
inhibition. FASEB J 23:2710–2726.
Mielcarek M, Inuabasi L, Bondulich MK, Muller T, Osborne GF, Franklin SA,
Smith DL, Neueder A, Rosinski J, Rattray I, Protti A, Bates GP. 2014. Dysfunc-
tion of the CNS-heart axis in mouse models of Huntington’s disease. PLoS
Genet 10:e1004550.
Mielcarek M, Toczek M, Smeets CJ, Franklin SA, Bondulich MK, Jolinon N,
Muller T, Ahmed M, Dick JR, Piotrowska I, Greensmith L, Smolenski RT, Bates
Jansen et al.: Huntington Aggregation in Neurons and Glia
Month 2016 11
GP. 2015. HDAC4-myogenin axis as an important marker of HD-related skele-
tal muscle atrophy. PLoS Genet 11:e1005021.
Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP. 2009. Formation of
polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150
knock-in mouse model of Huntington’s disease. PLoS One 4:e8025.
Morrison PJ, Harding-Lester S, Bradley A. 2011. Uptake of Huntington dis-
ease predictive testing in a complete population. Clin Genet 80:281–286.
Myers RH, Vonsattel JP, Paskevich PA, Kiely DK, Stevens TJ, Cupples LA,
Richardson EP, Bird ED. 1991. Decreased Neuronal and Increased Oligoden-
droglial Densities in Huntington’s Disease Caudate Nucleus. J Neuropathol
Exp Neurol 50:729–742.
Nucifora LG, Burke KA, Feng X, Arbez N, Zhu S, Miller J, Yang G, Ratovitski
T, Delannoy M, Muchowski PJ, Finkbeiner S, Legleiter J, Ross CA, Poirier
MA. 2012. Identification of novel potentially toxic oligomers formed in vitro
from mammalian-derived expanded huntingtin exon-1 protein. J Biol Chem
287:16017–16028.
Orre M, Kamphuis W, Osborn LM, Jansen AH, Kooijman L, Bossers K, Hol
EM. 2014a. Isolation of glia from Alzheimer’s mice reveals inflammation and
dysfunction. Neurobiol Aging 35:2746–2760.
Orre M, Kamphuis W, Dooves S, Kooijman L, Chan ET, Kirk CJ, Dimayuga
Smith V, Koot S, Mamber C, Jansen AH, Ovaa H, Hol EM. 2013. Reactive
glia show increased immunoproteasome activity in Alzheimer’s disease. Brain
136:1415–1431.
Orre M, Kamphuis W, Osborn LM, Melief J, Kooijman L, Huitinga I, Klooster
J, Bossers K, Hol EM. 2014b. Acute isolation and transcriptome characteriza-
tion of cortical astrocytes and microglia from young and aged mice. Neuro-
biol Aging 35:1–14.
Pekny M, Pekna M, Messing A, Steinhauser C, Lee JM, Parpura V, Hol EM,
Sofroniew MV, Verkhratsky A. 2016. Astrocytes: a central element in neuro-
logical diseases. Acta Neuropathol 131:323–345.
Rujano MA, Bosveld F, Salomons FA, Dijk F, van Waarde MA, van der Want
JJ, de Vos RA, Brunt ER, Sibon OC, Kampinga HH. 2006. Polarised asymmet-
ric inheritance of accumulated protein damage in higher eukaryotes. PLoS
Biol 4:e417.
Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K, Bhide
PG, Vonsattel JP, DiFiglia M. 2001. Early and progressive accumulation of
reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol
60:161–172.
Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates
GP. 2001. Centrosome disorganization in fibroblast cultures derived from R6/
2 Huntington’s disease (HD) transgenic mice and HD patients. Hum Mol
Genet 10:2425–2435.
Schafer DP, Lehrman EK, Stevens B. 2013. The? quad-partite? synapse:
Microglia-synapse interactions in the developing and mature CNS. GLIA 61:
24–36.
Seidel K, Siswanto S, Fredrich M, Bouzrou M, Brunt ER, van Leeuwen FW,
Kampinga HH, Korf HW, Rub U, den Dunnen WF. 2016. Polyglutamine
aggregation in Huntington’s disease and spinocerebellar ataxia type 3: similar
mechanisms in aggregate formation. Neuropathol Appl Neurobiol 42:153–
166.
Sharma K, Schmitt S, Bergner CG, Tyanova S, Kannaiyan N, Manrique-Hoyos
N, Kongi K, Cantuti L, Hanisch UK, Philips MA, Rossner MJ, Mann M, Simons
M. 2015. Cell type- and brain region-resolved mouse brain proteome. Nat
Neurosci 18:1819–1831.
Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ. 2005. Expression of mutant
huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 171:
1001–1012.
Silvestroni A, Faull RL, Strand AD, Moller T. 2009. Distinct neuroinflammatory
profile in post-mortem human Huntington’s disease. Neuroreport 20:1098–
1103.
Simmons DA, Casale M, Alcon B, Pham N, Narayan N, Lynch G. 2007. Ferri-
tin accumulation in dystrophic microglia is an early event in the development
of Huntington’s disease. GLIA 55:1074–1084.
Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H,
Hersch SM, Ferrante RJ. 2005. Chronology of behavioral symptoms and neu-
ropathological sequela in R6/2 Huntington’s disease transgenic mice.
J Comp Neurol 490:354–370.
Su P, Zhang J, Wang D, Zhao F, Cao Z, Aschner M, Luo W. 2016. The role of
autophagy in modulation of neuroinflammation in microglia. Neuroscience
319:155–167.
Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ, Piccini P.
2007. Microglial activation in presymptomatic Huntington’s disease gene car-
riers. Brain 130:1759–1766.
Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Haustein MD, Anderson MA,
Mody I, Olsen ML, Sofroniew MV, Khakh BS. 2014. Astrocyte Kir4.1 ion chan-
nel deficits contribute to neuronal dysfunction in Huntington’s disease model
mice. Nat Neurosci 17:694–703.
Vives V, Alonso G, Solal AC, Joubert D, Legraverend C. 2003. Visualization
of S100B-positive neurons and glia in the central nervous system of EGFP
transgenic mice. J Comp Neurol 457:404–419.
Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, Moffitt H,
Sathasivam K, Bates GP. 2007. The Hdh(Q150/Q150) knock-in mouse model
of HD and the R6/2 exon 1 model develop comparable and widespread
molecular phenotypes. Brain Res Bull 72:83–97.
Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, Phatnani
HP, Guarnieri P, Caneda C, Ruderisch N, Deng S, Liddelow SA, Zhang C,
Daneman R, Maniatis T, Barres BA, Wu JQ. 2014. An RNA-sequencing tran-
scriptome and splicing database of glia, neurons, and vascular cells of the
cerebral cortex. J Neurosci 34:11929–11947.
Zhang Y, Sloan S, Clarke L, Caneda C, Plaza C, Blumenthal P, Vogel H,
Steinberg G, Edwards MB, Li G, Duncan IIIJ, Cheshier S, Shuer L, Chang E,
Grant G, Gephart M, Barres B. 2016. Purification and characterization of pro-
genitor and mature human astrocytes reveals transcriptional and functional
differences with mouse. Neuron 89:37–53.
12 Volume 00, No. 00
